Although Fampridine, known commercially as Fampyra, is not covered by Health Service Executive-funded drug schemes, it has been provided free to patients for the past 2½ years under a clinical trial by the manufacturer, Biogen. Photograph: Biogen

Multiple sclerosis patients will have to pay up to €400 per month from today for a drug to improve mobility which was previously provided free of char(...)

Minister of State for Primary Care Alex White: said Biogen had told the HSE it intended to submit a revised application to the NCPE. Photograph: Alan Betson/The Irish Times

The makers of a drug that helps people with multiple sclerosis to walk are to make a fresh application to have it covered by the Health Service Execu(...)

The curve of the German share price index DAX board is pictured at the Frankfurt stock exchange. Photograph: Reuters/Fabrizio Bensch

A boost for mining companies and Sky Deutschland helped drive European stocks rose to their highest level in more than six years. Commodity produce(...)

Netflix continued its downward trend, slipping 1.6 per cent to $358.50.

Stocks rose yesterday as data emerged showing confidence is up in a number of European economies and in the US. Traders (...)

The  front of the European Central Bank  headquarters in Frankfurt, Germany: the ECB  has kept its benchmark interest rate unchanged at a record low 0.25 per cent

Tom Lyons Senior Business Correspondent European stocks were little changed, paring earlier gains, after the European Central Bank kept i(...)

Perrigo  president and chief executive Joe Papa. Photograph: Brenda Fitzsimons

In a statement, Perrigo said it had done a deal with Canadian group Transition Therapeutics, the partner in the ELND005 programme(...)

Biogen Idec said today its new, high-profile oral multiple sclerosis drug Tecfidera had sales of $398 million in the fourth quarter, easily exceeding (...)

For your diary

TODAYResults: Alkermes; Apple; Biogen Idec; TNT Express.Indicators: US pending home sales (Sep); German retail sales (Sep); Japanese unemployment rate(...)

investor Carl Icahn had hoped to head off a September 12th Dell special shareholders’ vote on a takeover proposal that the hedge fund billionaire and other major investors argue severely undervalues the company. Photograph: Reuters/Chip East

Activist investor Carl Icahn’s legal effort to derail a $25 billion takeover of Dell Inc stalled yesterday after a judge refused to fast-track his law(...)

Elan chief executive Kelly Martin, a former  Merrill Lynch banker, took the helm in 2003, drastically paring down the company and opting to focus on the development of multiple sclerosis drug Tysabri.  Photograph: Alan Betson

The sale of Elan to Perrigo marks the end of a rollercoaster ride for the Irish drugmaker, which has fended off three takeover bids by private equity (...)